Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acanthopanax senticosus polysaccharide (ASPS) is a bioactive carbohydrate polymer extracted from the roots or rhizomes of *Acanthopanax senticosus*, commonly known as Siberian Ginseng or Ciwujia. It is widely recognized for its potent immunomodulatory, anti-tumor, and anti-inflammatory properties. Research indicates that ASPS exerts anti-colorectal cancer effects by modulating the gut microbiota-metabolism-immune axis, specifically by inhibiting the TLR4/MyD88/NF-κB signaling pathway. This inhibition leads to reduced inflammatory cytokine production and metabolic reprogramming of tumor cells. Additionally, ASPS is utilized as an adaptogen to enhance immune function and alleviate fatigue.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acanthopanax senticosus polysaccharide.